Is ATRA research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ATRA. It does not provide personalized investment advice.

ATRA (Atara Biotherapeutics, Inc) Stock Analysis - Financials

Atara Biotherapeutics, Inc (ATRA) is a publicly traded Healthcare sector company. As of July 27, 2026, ATRA trades at $7.90 with a market cap of $71.18M and a P/E ratio of -10.39. ATRA moved -2.33% today. Year to date, ATRA is -55.82%; over the trailing twelve months it is -35.40%. Its 52-week range spans $3.92 to $19.15. Analyst consensus is buy with an average price target of $13.67. Rallies surfaces ATRA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are ATRA's key financials?

ATRA financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. ATRA recently traded at $7.90. Market cap is $71.18M. P/E ratio is -10.39. Revenue is $23.14M.

ATRA Key Metrics

Key financial metrics for ATRA
Metric	Value
Price	$7.90
Market Cap	$71.18M
P/E Ratio	-10.39
EPS	$-0.76
Dividend Yield	0.00%
52-Week High	$19.15
52-Week Low	$3.92
Volume	0
Avg Volume	0
Revenue (TTM)	$23.14M
Net Income	$-9.47M
Gross Margin	0.00%

ATRA Analyst Consensus

3 analysts cover ATRA: 0 strong buy, 2 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $13.67.

Common questions about ATRA

What are ATRA's key financials?: ATRA financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. ATRA recently traded at $7.90. Market cap is $71.18M. P/E ratio is -10.39. Revenue is $23.14M.
Is ATRA research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ATRA. It does not provide personalized investment advice.